4.7 Article

Isolevuglandins covalently modify phosphatidylethanolamines in vivo: Detection and quantitative analysis of hydroxylactam adducts

Journal

FREE RADICAL BIOLOGY AND MEDICINE
Volume 47, Issue 11, Pages 1539-1552

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2009.09.003

Keywords

Levuglandin; Isolevuglandin; Isoketal; Phosphatidylethanolamine; Oxidative stress; Biomarker; Free radical; Mass spectrometry; Protein adduct

Funding

  1. NIH [AA013868, AA011975, GM021249, HL087018, EY014239]
  2. State of Ohio [05-29]

Ask authors/readers for more resources

Levuglandins (LGs) and isolevuglandins (isoLGs, also called isoketals or isoKs) are extraordinarily reactive products of cyclooxygenase- and free radical-induced oxidation of arachidonates. We now report the detection in vivo and quantitative analysis of LG/isoLG adducts that incorporate the amino group of phosphatidylethanolamines (PEs) into LG/isoLG-hydroxylactams. Notably, LC-MS/MS detection of these hydroxylactams is achieved with samples that are an order of magnitude smaller and sample processing is much simpler and less time consuming than required for measuring protein-derived LG/isoLG-lysyl lactams. A key feature of our protocol is treatment of biological phospholipid extracts with phospholipase A(2) to generate mainly 1-palmitoyl-2-lysoPE-hydroxylactams from heterogeneous mixtures of phospholipids with a variety of acyl groups on the 2 position. Over 160% higher mean levels of LG/isoLG-PE-hydroxylactam (P<0.001) were detected in liver from chronic ethanol-fed mice (32.4 +/- 6.3 ng/g, n = 6) compared to controls (12.1 +/- 1.5 ng/g, n = 4), and mean levels in plasma from patients with age-related macular degeneration (5.2 +/- 0.4 ng/ml, n = 15) were elevated similar to 53% (P<0.0001) compared to those of healthy volunteers (3.4 +/- 0.1 ng/ml, n = 15). just as LG/isoLG-protein adducts provide a dosimeter of oxidative injury, this study suggests that LG/isoLG-PE-hydroxylactams are potential biomarkers for assessing risk for oxidative stress-stimulated diseases. (C) 2009 Elsevier Inc. All rights reserved

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available